Everything below concerns Cardarine. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
== History == In 1908, what appears to be the first case of Urbach–Wiethe disease was reported by Friedrich Siebenmann, a professor of otolaryngology in Basel, Switzerland. In 1925, Friedrich Miescher, a Swiss dermatologist, reported on three similar patients. An official report of Urbach–Wiethe disease was first described in 1929 by a Viennese dermatologist and otorhinolaryngologist, Urbach and Wiethe. Its original name of 'lipoidosis cutis et mucosae' was changed to 'lipoid proteinosis cutis et mucosae' due to Urbach's belief that the condition was due to abnormal lipid and protein deposits within the tissues. Some have debated as to whether or not the disease is actually a form of mucopolysaccharidosis, amyloidosis, or even porphyria. The discovery of the Urbach–Wiethe disease causing mutation to the ECM1 gene has now provided a definitive way to differentiate Urbach–Wiethe disease from these other conditions. A woman with Urbach–Wiethe disease, S.M., was a woman unable to feel fear. She has been extensively studied, which helped determine the function of the amygdala.
=== NADPH === NADPH is produced from NADP+. The major source of NADPH in animals and other non-photosynthetic organisms is the pentose phosphate pathway, by glucose-6-phosphate dehydrogenase (G6PDH) in the first step. The pentose phosphate pathway also produces pentose, another important part of NAD(P)H, from glucose. Some bacteria also use G6PDH for the Entner–Doudoroff pathway, but NADPH production remains the same. Ferredoxin–NADP+ reductase, present in all domains of life, is a major source of NADPH in photosynthetic organisms including plants and cyanobacteria. It appears in the last step of the electron chain of the light reactions of photosynthesis. It is used as reducing power for the biosynthetic reactions in the Calvin cycle to assimilate carbon dioxide and help turn the carbon dioxide into glucose. It has functions in accepting electrons in other non-photosynthetic pathways as well: it is needed in the reduction of nitrate into ammonia for plant assimilation in nitrogen cycle and in the production of oils. There are several other lesser-known mechanisms of generating NADPH, all of which depend on the presence of mitochondria in eukaryotes. The key enzymes in these carbon-metabolism-related processes are NADP-linked isoforms of malic enzyme, isocitrate dehydrogenase (IDH), and glutamate dehydrogenase. In these reactions, NADP+ acts like NAD+ in other enzymes as an oxidizing agent. The isocitrate dehydrogenase mechanism appears to be the major source of NADPH in fat and possibly also liver cells. These processes are also found in bacteria.
Camille Étienne, born 29 May 1998 in Grenoble, Auvergne-Rhone-Alpes, is a French environmental activist. A member of the duo Avant l'orage (Before the Storm), along with director Solal Moisan, she takes part in and leads acts of civil disobedience, lobbying of political and economic decision makers and raising public awareness.
Sources: en.wikipedia.org
==== United States ==== TMA-2 is not an explicitly controlled substance in the United States. However, it is a positional isomer of 3,4,5-trimethoxyamphetamine (TMA), and thus may be considered a Schedule I controlled substance in this country similarly to TMA.
=== Aortic dissection === Fluoroquinolones can increase the rate of rare but serious tears in the aorta by 31% compared to other antibiotics. People at increased risk include those with aortic aneurysm, hypertension, certain genetic conditions such as Marfan syndrome and Ehlers–Danlos syndrome, and the elderly. For these people, fluoroquinolones should be used only when no other treatment options are available. One year after the warning announcement, prescribing behaviors were reported to have remained unchanged.
Cordelia, afraid that her brother might tell him of James' grandfather, eavesdrops on her brother and Charles' conversation and finds out that Alastair and Charles are gay and Charles was marrying Ariadne for power only. He was scared of rejection by the society and hence couldn't publicly display his sexual orientation. The next morning, James visits Cordelia and they, along with Matthew and Lucie pay a visit to Emmanuel Gast. However, he is already dead. Lucie summons his ghost and learns that he had raised the demon who was wreaking havoc over London. He claimed that he knew her grandfather, but she banished him before he could reveal much. Later they find splinters of wood with strange inscriptions. The four head back to the institute. Charles arrives in a carriage, bringing Grace and a bloodied Tatiana to the Institute. Once Tatiana is being treated in their infirmary, Grace pulls James aside to talk to him. James takes Grace aside where she informs him that she is now engaged to Charles - who had broken off his engagement with Ariadne whilst she was unconscious. Grace demands her bracelet back from him and when he returns it, he feels physical pain from the separation. He goes to the Blackfriars Bridge to relieve his heartache. Grace finds Matthew and tells him what has transpired. Before she leaves, she seemingly holds Matthew in place with words alone and kisses him. She threatens to tell James about this kiss if Matthew ever breathes a word of their conversation to anyone.
== History == Zalsupindole was first described in the scientific literature by David E. Olson and colleagues in 2021. It was developed by Olson's lab at the University of California, Davis and at his company Delix Therapeutics. The drug was first synthesized in 2019. It was initially described under the name AAZ-A-154 and then by the name DLX-001 before receiving the name zalsupindole.
Sources: en.wikipedia.org
== Chemical properties == Azidophenylalanine has the molecular formula C9H10N4O2 and a molecular weight of 206.20 g/mol. Its IUPAC name is (2S)-2-amino-3-(4-azidophenyl)propanoic acid. It appears as an off-white solid and is soluble in water, DMSO, and DMF. As with many other azides, the isolated compound exhibits explosive properties. It is light-sensitive and should be stored at -20 °C in the dark.
=== Ed Conner === Ed Conner is played by Ned Beatty. Ed is Dan's father, a charming traveling salesman who always brings presents for the grandchildren. Dan has a troubled history with his father, and Roseanne tries to keep the peace between the two. The family likes Ed, but Dan grew up feeling neglected with Ed seldom being home and his mother's mental illness, in addition to verbal slights that Ed targets towards Dan (e.g., when Dan questions Ed dating Crystal, Ed makes a rude crack about Dan being "interested" in Crystal). It usually takes little to no time for Dan to become annoyed by his father's presence. All this was unknown to Dan until Crystal revealed it to Roseanne. Ed hoped to provide Dan with at least one stable parent as he would often be gone on sales trips during Dan's adolescence. He wants to learn from his past actions and be a better father and husband. He loves his son despite their troubled relationship, and also loves the rest of his family. He marries Crystal and has two children with her (Ed Jr. and Angela), who are significantly younger than their half-brother, Dan. He is said to have died in The Conners; it appears he was no longer with Crystal and was living alone.
While this terminology results in a simplified way of dealing with kinetic effects relating to the maximum velocity of the Michaelis–Menten equation, it highlights potential problems with the term used to describe effects relating to the Km. The Km relating to the affinity of the enzyme for the substrate should in most cases relate to potential changes in the binding site of the enzyme which would directly result from enzyme inhibitor interactions. As such a term similar to the delta Vmax term proposed above to modulate Vmax should be appropriate in most situations:
== Drug interactions == Smoking is known to increase levels of liver enzymes that break down drugs and toxins. That means that drugs cleared by these enzymes are cleared more quickly in smokers, which may result in the drugs not working. Specifically, levels of CYP1A2 and CYP2A6 are induced: substrates for 1A2 include caffeine and tricyclic antidepressants such as amitriptyline; substrates for 2A6 include the anticonvulsant valproic acid.
In conjunction, the Russian Interior Ministry issued an arrest warrant for the International Criminal Court's Prosecutor Karim Ahmad Khan, who was responsible for issuing Putin's arrest warrant in March 2023, while the Prosecutor-General of Russia deemed the environmental organization Greenpeace an "undesirable organization", calling it "a threat to the foundations of the constitutional order and security" of the country for interfering in the "internal affairs of the state" and spreading "anti-Russian propaganda" and calling for economic sanctions. The order prompted Greenpeace to halt its operations in Russia. Yevgeny Roizman, former mayor of Yekaterinburg and opposition politician, was convicted and fined 260,000 rubles ($3245) for discrediting the Russian army over comments made regarding the war in Ukraine. Ukraine was losing some 10,000 drones a month due to Russian electronic warfare according to report by the Royal United Services Institute.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.